The Central Blood Laboratories Authority's Activity and Current Issues Update Report May 1988 was published. Read more about The Central Blood Laboratories Authority's Activity and Current Issues Update Report May 1988 was published.
Malcolm Harris wrote a letter to Ms Westbrook regarding the benefit of transfer pricing to regions. Under the cross-charging system, BPL paid regional transfusion centres a national price for supplying plasma and the regions paid BPL for the blood products supplied. Read more about Malcolm Harris wrote a letter to Ms Westbrook regarding the benefit of transfer pricing to regions. Under the cross-charging system, BPL paid regional transfusion centres a national price for supplying plasma and the regions paid BPL for the blood products supplied.
A letter from S Murray of the NBTS to Dr Maycock stated that he was quite sure that some clinicians would not be satisfied with halving the amount of cryoprecipitate they were supplied, even if given additional AHG. Read more about A letter from S Murray of the NBTS to Dr Maycock stated that he was quite sure that some clinicians would not be satisfied with halving the amount of cryoprecipitate they were supplied, even if given additional AHG.
B Gidden of the DHSS stated that the arrival of commercial material in quantity precipitated a demand from the NHS which had become more and more insistent, which could not have been anticipated at the time forecast estimates were drawn up a year earlier. Read more about B Gidden of the DHSS stated that the arrival of commercial material in quantity precipitated a demand from the NHS which had become more and more insistent, which could not have been anticipated at the time forecast estimates were drawn up a year earlier.
A review considered various options which included handing over the fractionation process to a commercial industry and concluded that increasing capacity at UK facilities was more viable. Read more about A review considered various options which included handing over the fractionation process to a commercial industry and concluded that increasing capacity at UK facilities was more viable.
With regards to a possible takeover of BPL by Beecham, Peter Wormland of the DHSS stated that was important to reach a decision in principle regarding whether they should reject the commercial option or decide whether they intend to implement it, subject to negations, highlighting issues with further delays to a decision. Read more about With regards to a possible takeover of BPL by Beecham, Peter Wormland of the DHSS stated that was important to reach a decision in principle regarding whether they should reject the commercial option or decide whether they intend to implement it, subject to negations, highlighting issues with further delays to a decision.
Despite the decision to waive Crown immunity, there was some flexibility for NHS facilities. Although manufacturing licenses were not mandated by statute for NHS manufacturing facilities, the policy was that they should still comply with the standards which the Medicines Division would require from commercial firms. Read more about Despite the decision to waive Crown immunity, there was some flexibility for NHS facilities. Although manufacturing licenses were not mandated by statute for NHS manufacturing facilities, the policy was that they should still comply with the standards which the Medicines Division would require from commercial firms.
Ministers were asked to consider and agree whether: that there should be a short-term upgrade to BPL even though it would fall short of recommendations of the Medicines Inspectorate; a decision in principle to rebuild BPL but without commitment to method or timing; and to conduct a further exploration of options for rebuilding within the NHS or in collaboration with industry. Read more about Ministers were asked to consider and agree whether: that there should be a short-term upgrade to BPL even though it would fall short of recommendations of the Medicines Inspectorate; a decision in principle to rebuild BPL but without commitment to method or timing; and to conduct a further exploration of options for rebuilding within the NHS or in collaboration with industry.
In December 1979, a submission was made to ministers on the future of BPL and the problems the department faced in terms of the present and future operation of this facility. Read more about In December 1979, a submission was made to ministers on the future of BPL and the problems the department faced in terms of the present and future operation of this facility.
Investigations in relation to upgrading BPL showed that no British firm had the necessary expertise in the manufacture of blood products and only foreign firms had approached the Department with a view to processing British plasma on the existing basis and to process and re-export plasma from overseas. Read more about Investigations in relation to upgrading BPL showed that no British firm had the necessary expertise in the manufacture of blood products and only foreign firms had approached the Department with a view to processing British plasma on the existing basis and to process and re-export plasma from overseas.